420 related articles for article (PubMed ID: 11303623)
21. A novel germline mutation of PTEN associated with brain tumours of multiple lineages.
Staal FJ; van der Luijt RB; Baert MR; van Drunen J; van Bakel H; Peters E; de Valk I; van Amstel HK; Taphoorn MJ; Jansen GH; van Veelen CW; Burgering B; Staal GE
Br J Cancer; 2002 May; 86(10):1586-91. PubMed ID: 12085208
[TBL] [Abstract][Full Text] [Related]
22. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization.
Bigner SH; Matthews MR; Rasheed BK; Wiltshire RN; Friedman HS; Friedman AH; Stenzel TT; Dawes DM; McLendon RE; Bigner DD
Am J Pathol; 1999 Aug; 155(2):375-86. PubMed ID: 10433931
[TBL] [Abstract][Full Text] [Related]
23. KLF6, a putative tumor suppressor gene, is mutated in astrocytic gliomas.
Jeng YM; Hsu HC
Int J Cancer; 2003 Jul; 105(5):625-9. PubMed ID: 12740910
[TBL] [Abstract][Full Text] [Related]
24. Silencing of the PTEN tumor-suppressor gene in anaplastic thyroid cancer.
Frisk T; Foukakis T; Dwight T; Lundberg J; Höög A; Wallin G; Eng C; Zedenius J; Larsson C
Genes Chromosomes Cancer; 2002 Sep; 35(1):74-80. PubMed ID: 12203792
[TBL] [Abstract][Full Text] [Related]
25. Nogo-a expression in glial CNS tumors: a tool to differentiate between oligodendrogliomas and other gliomas?
Kuhlmann T; Gutenberg A; Schulten HJ; Paulus W; Rohde V; Bruck W
Am J Surg Pathol; 2008 Oct; 32(10):1444-53. PubMed ID: 18685489
[TBL] [Abstract][Full Text] [Related]
26. WT1 expression increases with malignancy and indicates unfavourable outcome in astrocytoma.
Rauscher J; Beschorner R; Gierke M; Bisdas S; Braun C; Ebner FH; Schittenhelm J
J Clin Pathol; 2014 Jul; 67(7):556-61. PubMed ID: 24607494
[TBL] [Abstract][Full Text] [Related]
27. Tumor suppressor gene alterations in malignant gliomas: histopathological associations and prognostic evaluation.
James CD; Galanis E; Frederick L; Kimmel DW; Cunningham JM; Atherton-Skaff PJ; O'Fallon JR; Jenkins RB; Buckner JC; Hunter SB; Olson JJ; Scheithauer BW
Int J Oncol; 1999 Sep; 15(3):547-53. PubMed ID: 10427138
[TBL] [Abstract][Full Text] [Related]
28. PTEN mutations in malignant gliomas and their relation with meningeal gliomatosis.
Izumoto S; Ohnishi T; Kanemura H; Arita N; Maruno M; Moriuchi T; Suzuki S; Yoshimine T
J Neurooncol; 2001 May; 53(1):21-6. PubMed ID: 11678426
[TBL] [Abstract][Full Text] [Related]
29. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas.
Broderick DK; Di C; Parrett TJ; Samuels YR; Cummins JM; McLendon RE; Fults DW; Velculescu VE; Bigner DD; Yan H
Cancer Res; 2004 Aug; 64(15):5048-50. PubMed ID: 15289301
[TBL] [Abstract][Full Text] [Related]
30. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme.
Smith JS; Tachibana I; Passe SM; Huntley BK; Borell TJ; Iturria N; O'Fallon JR; Schaefer PL; Scheithauer BW; James CD; Buckner JC; Jenkins RB
J Natl Cancer Inst; 2001 Aug; 93(16):1246-56. PubMed ID: 11504770
[TBL] [Abstract][Full Text] [Related]
31. PTEN mutations in gliomas and glioneuronal tumors.
Duerr EM; Rollbrocker B; Hayashi Y; Peters N; Meyer-Puttlitz B; Louis DN; Schramm J; Wiestler OD; Parsons R; Eng C; von Deimling A
Oncogene; 1998 Apr; 16(17):2259-64. PubMed ID: 9619835
[TBL] [Abstract][Full Text] [Related]
32. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in advanced gastric carcinomas.
Wang JY; Huang TJ; Chen FM; Hsieh MC; Lin SR; Hou MF; Hsieh JS
Virchows Arch; 2003 May; 442(5):437-43. PubMed ID: 12695913
[TBL] [Abstract][Full Text] [Related]
33. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines.
Teng DH; Hu R; Lin H; Davis T; Iliev D; Frye C; Swedlund B; Hansen KL; Vinson VL; Gumpper KL; Ellis L; El-Naggar A; Frazier M; Jasser S; Langford LA; Lee J; Mills GB; Pershouse MA; Pollack RE; Tornos C; Troncoso P; Yung WK; Fujii G; Berson A; Steck PA
Cancer Res; 1997 Dec; 57(23):5221-5. PubMed ID: 9393738
[TBL] [Abstract][Full Text] [Related]
34. Genetic alterations of the tumor suppressor gene PTEN/MMAC1 in human brain metastases.
Hahn M; Wieland I; Koufaki ON; Görgens H; Sobottka SB; Schackert G; Schackert HK
Clin Cancer Res; 1999 Sep; 5(9):2431-7. PubMed ID: 10499615
[TBL] [Abstract][Full Text] [Related]
35. Loss of heterozygosity and mutational analysis of the PTEN/MMAC1 gene in synchronous endometrial and ovarian carcinomas.
Lin WM; Forgacs E; Warshal DP; Yeh IT; Martin JS; Ashfaq R; Muller CY
Clin Cancer Res; 1998 Nov; 4(11):2577-83. PubMed ID: 9829719
[TBL] [Abstract][Full Text] [Related]
36. PTEN/MMAC1 mutations and EGFR amplification in glioblastomas.
Liu W; James CD; Frederick L; Alderete BE; Jenkins RB
Cancer Res; 1997 Dec; 57(23):5254-7. PubMed ID: 9393744
[TBL] [Abstract][Full Text] [Related]
37. Intragenic PTEN/MMAC1 loss of heterozygosity in conventional (clear-cell) renal cell carcinoma is associated with poor patient prognosis.
Velickovic M; Delahunt B; McIver B; Grebe SK
Mod Pathol; 2002 May; 15(5):479-85. PubMed ID: 12011252
[TBL] [Abstract][Full Text] [Related]
38. Genetic alterations in pediatric high-grade astrocytomas.
Cheng Y; Ng HK; Zhang SF; Ding M; Pang JC; Zheng J; Poon WS
Hum Pathol; 1999 Nov; 30(11):1284-90. PubMed ID: 10571506
[TBL] [Abstract][Full Text] [Related]
39. Molecular genetic analysis of non-astrocytic gliomas.
Tong CY; Ng HK; Pang JC; Hui AB; Ko HC; Lee JC
Histopathology; 1999 Apr; 34(4):331-41. PubMed ID: 10231401
[TBL] [Abstract][Full Text] [Related]
40. Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway.
Unoki M; Nakamura Y
Oncogene; 2001 Jul; 20(33):4457-65. PubMed ID: 11494141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
